Neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 as prognostic markers for advanced pancreatic cancer patients receiving first-line chemotherapy

Figure 2 Overall survival and progression-free survival. A and B: Overall survival (A) and progression-free survival (B) of the groups divided by carbohydrate antigen 19-9 response and post-treatment neutrophil-to-lymphocyte ratio. All groups were significantly different from each other in the overall survival and progression-free survival curves and Group 1 showed better overall survival and progression-free survival than others. CA19-9: Carbohydrate antigen 19-9; NLR: Neutrophil-to-lymphocyte ratio.